ONWARD MEDICAL BV EO -12 - Asset Resilience Ratio

Latest as of June 2024: 16.01%

ONWARD MEDICAL BV EO -12 (63E) has an Asset Resilience Ratio of 16.01% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 63E current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€7.50 Million
≈ $8.77 Million USD Cash + Short-term Investments

Total Assets

€46.85 Million
≈ $54.78 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how ONWARD MEDICAL BV EO -12's Asset Resilience Ratio has changed over time. See net assets of ONWARD MEDICAL BV EO -12 for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ONWARD MEDICAL BV EO -12's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ONWARD MEDICAL BV EO -12 (63E) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €7.50 Million 16.01%
Total Liquid Assets €7.50 Million 16.01%

Asset Resilience Insights

  • Good Liquidity Position: ONWARD MEDICAL BV EO -12 maintains a healthy 16.01% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

ONWARD MEDICAL BV EO -12 Industry Peers by Asset Resilience Ratio

Compare ONWARD MEDICAL BV EO -12's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 33.70%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
Biotechnology 11.64%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
Biotechnology 2.21%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 82.25%

Annual Asset Resilience Ratio for ONWARD MEDICAL BV EO -12 (2022–2022)

The table below shows the annual Asset Resilience Ratio data for ONWARD MEDICAL BV EO -12.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 26.11% €20.00 Million
≈ $23.38 Million
€76.59 Million
≈ $89.55 Million
--
pp = percentage points

About ONWARD MEDICAL BV EO -12

F:63E Germany Biotechnology
Market Cap
$230.45 Million
€197.11 Million EUR
Market Cap Rank
#16832 Global
#1597 in Germany
Share Price
€2.84
Change (1 day)
+1.98%
52-Week Range
€2.59 - €5.56
All Time High
€12.92
About

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more